QINGDAO, China, November 1, 2021 / PRNewswire / – MGI Tech Co., Ltd. (MGI), a global leader and innovator in life sciences, presented a series of performance upgrades to its gene sequencing platforms * and a new multiplex PCR platform at 16e International Conference on Genomics (ICG-16) tenuous in Qingdao, China.
As one of three global companies capable of mass-producing high throughput clinical sequencers, MGI is committed to developing core tools and technologies to lead the life science industry through intelligent innovations. . At this year’s ICG, MGI released the Enhanced DNBSEQ-T7 High Throughput Sequencing Reagent Set * and the DNBSEQ-G400 * High Throughput Sequencing Reagent Set (FCS PE300). Additionally, MGI has launched its customized ATOPlex platform, based on MGI’s proprietary ultra-high multiplex PCR technology.
As a provider of tools for the life sciences, MGI constantly strives to develop industrial innovations. MGI’s commitment to investing heavily in research and development enables the company to advance the status quo of the global genome sequencing industry by providing customers with high-quality, innovative life science tools. and affordable.
Enhanced * DNBSEQ-T7 Sequencing Reagent Set V2.0 * can now provide higher and more stable data output
Since its release in 2018, the DNBSEQ-T7 * has been the highest throughput sequencer to date and has achieved a number of breakthroughs, most notably being the first 4-chip sequencing platform, complementing the PE150 at full capacity. charges between 24 and 30 hours, generating 6TB of data per day and completing up to 60 entire human genomes per day.
During ICG-16, MGI announced the launch of the new V2.0 * Sequencing Reagent Set for DNBSEQ-T7 *, offering higher and more stable data output. Powered by this new set of sequencing reagents *, the DNBSEQ-T7 * will further accelerate scientific advancements in whole genome sequencing, whole exon sequencing and metagenome sequencing through its high speed, flexible and high speed advantages. very high speed.
These enhanced features further reduce the sequencing mismatch rate, duplication rate, and cost of single-sample sequencing. In addition, it will further improve the efficiency of data use, accuracy and sensitivity of variation detection.
MGI’s New Breakthrough to Achieve Ultra-High Throughput 300bp Read Length Sequencing Reagent Set *
Massively Parallel Sequencing (MPS) based sequencing platform has been widely used for its advantages including high throughput, high precision and low cost. However, MPS sequencing read length has always been a challenge for the industry. There are very few MPS platforms on the market that can achieve a sequencing read length of 300 bp.
Based on MGI’s innovative Rolling Circle Amplification (RCA) and Loading DNB technology – MLG ™ (Make DNB, Load DNB and Grow), the enhanced FCS PE300 sequencing reagent set from MGI * for the high throughput genetic sequencer DNBSEQ -G400 * can produce up to 180 GB of PE300 data in a single pass with read lengths of up to 300 bp in pairs. The DNBSEQ-G400 * can output 360 GB of data when loaded with two chips and can run two sets of reagents * at the same time to achieve 24x faster throughput compared to other platforms currently available on the market.
MGI multiplex PCR technology enables the development of customized and customized panels for targeted sequencing in a variety of applications
MGI is constantly striving to make new technological and application advances. Based on its multiplex PCR technology, MGI has developed a new customizable multiplex PCR platform called ATOPlex, allowing users to design custom panels in a wide range of 10-20,000 amplicons and develop their own workflow. targeted sequencing with a suitable library preparation module, also with MGI * sequencers.
With its unique core technical, ATOPlex single-tube multi-PCR technology can achieve automatic primer design while effectively reducing dimers, even when all operations have been performed in a single tube. Aiming to specialize in the customization of library preparation reagent, the ATOPlex platform covers DNA, RNA and DNA methylation, which is suitable for many industry sectors, such as medicine, food safety, agriculture, DTC (direct to customer), etc.
MGI (MGI Tech Co., Ltd.), headquartered in Shenzhen, is committed to creating core tools and technology to lead the life sciences through intelligent innovation. Based on its proprietary technology, MGI focuses on research and development, production and sale of sequencing instruments, reagents and related products to support research in life sciences, agriculture, precision medicine and health care. MGI is a leading producer of high throughput clinical gene sequencers, and its multi-omics platforms include genetic sequencing *, medical imaging and laboratory automation. MGI’s mission is to develop and promote advanced life science tools for future healthcare. For more information, please visit MGI website or connect us on Twitter, LinkedIn Where Youtube.
* Unless stated otherwise, not all sequencers and sequencing reagents are available in Germany, United States, Spain, UK, Hong Kong, Sweden, Belgium and Italy.
SOURCE MGI Tech Co., Ltd